Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium

• Type of Material: Article
• Authors: Wendy van Dorp, Erasmus University Medical Center; Renée L. Mulder, Emma Children's Hospital; Leontien C.M. Kremer, Emma Children's Hospital; Melissa M. Hudson, St Jude Children's Research Hospital; Marry M. van den Heuvel-Eibrink, Princess Maxima Center for Pediatric Oncology; Marleen H. van den Berg, Vrije Universiteit Medical Center; Jennifer M. Levine, Columbia University; Eline van Dulmen-den Broeder, Vrije Universiteit Medical Center; Natascia di Iorgi, University of Genoa; Assunta Albanese, St George’s University Hospitals NHS Foundation Trust; Saro H. Armenian, City of Hope; Smita Bhatia, University of Alabama Birmingham; Louis S. Constine, University of Rochester; Andreas Corrias, University of Turin; Rebecca Deans, University of New South Wales; Uta Dirksen, University Hospital Munster; Clarisa R. Gracia, University of Pennsylvania; Lars Hjorth, Lund University; Leah Kroon, Seattle Children's Hospital; Cornelis B Lambalk, Vrije Universiteit Medical Center; Wendy Landier, University of Alabama Birmingham; Gill Levitt, Great Ormond St Hospital for Children NHS Foundation Trust; Alison Leiper, Great Ormond St Hospital for Children NHS Foundation Trust; Lillian Meacham, Emory University; Alesandro Mussa, University of Turin; Sebastian J. Neggers, Erasmus Univ; Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Alberto Revelli, University of Torino; Hanneke M. van Santen, Wilhelmina Children’s Hospital; Roderick Skinner, Newcastle University; Andrew Toogood, University Hospitals Birmingham NHS Foundation Trust; William H. Wallace, Royal Hospital for Sick Children; Riccardo Haupt, Istituto Giannina Gaslini
• Language: English
• Date: 2016-10-01
• Publisher: American Society of Clinical Oncology
• Publication Version: Final Published Version
• Copyright Statement: © 2016 by American Society of Clinical Oncology.
• Final Published Version (URL): http://dx.doi.org/10.1200/JCO.2015.64.3288
• Title of Journal or Parent Work: Journal of Clinical Oncology
• ISSN: 0732-183X
• Volume: 34
• Issue: 28
• Start Page: 3440
• End Page: +
• Grant/Funding Information: Supported by the Pediatric Oncology Centre Society for Research (KOCR), Rotterdam, the Netherlands (W.v.D.); by the Dutch Cancer Society, Amsterdam, the Netherlands (UVA 2011-4938; R.L.M.); by Cancer Center Support (CORE) Grant No. CA21765 (R. Gilbertson, PI) to St Jude Children’s Research Hospital and the American Lebanese Syrian Associated Charities (ALSAC; M.M.H.); and by the 7th Framework Programme of the European Union, PanCareSurfUp (257505; L.C.N.K., R.H., L.H., R.S.).
• Keywords: FERTILITY PRESERVATION; GONADAL-FUNCTION; NATURAL MENOPAUSE; Life Sciences & Biomedicine; LONG-TERM SURVIVORS; BREAST-CANCER; MENSTRUAL-CYCLE; Oncology; SEX STEROID REPLACEMENT; Science & Technology; CLINICAL GUIDELINES; FOLLOW-UP; ANTI-MULLERIAN HORMONE
• Research Categories: Health Sciences, Oncology

Abstract

Purpose: Female survivors of childhood, adolescent, and young adult (CAYA) cancer who were treated with alkylating agents and/or radiation, with potential exposure of the ovaries, have an increased risk of premature ovarian insufficiency (POI). Clinical practice guidelines can facilitate these survivors' access to optimal treatment of late effects that may improve health and quality of survival; however, surveillance recommendations vary among the existing long-term follow-up guidelines, which impedes the implementation of screening. Patients and Methods: The present guideline was developed by using an evidence-based approach and summarizes harmonized POI surveillance recommendations for female survivors of CAYA cancer who were diagnosed at age < 25 years. The recommendations were formulated by an international multidisciplinary panel and graded according to the strength of the evidence and the potential benefit gained from early detection and intervention. The harmonized POI surveillance recommendations were developed by using a transparent process and are intended to facilitate care for survivors of CAYA cancer. Results and Conclusion: The harmonized set of POI surveillance recommendations is intended to be scientifically rigorous, to positively influence health outcomes, and to facilitate the care for female survivors of CAYA cancer.